| Identification | Back Directory | [Name]
UT-34 | [CAS]
2168525-92-4 | [Synonyms]
UT-34
1H-Pyrazole-1-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-4-fluoro-α-hydroxy-α-methyl-, (αS)- | [Molecular Formula]
C15H12F4N4O2 | [MDL Number]
MFCD32710281 | [MOL File]
2168525-92-4.mol | [Molecular Weight]
356.28 |
| Chemical Properties | Back Directory | [Boiling point ]
553.4±50.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (701.71 mM; Need ultrasonic) | [form ]
Solid | [pka]
12.25±0.29(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
UT-34 is a potent, selective, orally bioactive second-generation pan-androgen receptor (AR) antagonist and degrader, with IC50 values of 211.7 nM, 262.4 nM, and 215.7 nM for wild-type AR, F876L-AR, and W741L-AR, respectively. UT-34 binds to the ligand-binding domain (LBD) and functional 1 (AF-1) domain of AR and requires the ubiquitin-proteasome pathway for AR degradation. UT-34 has anti-prostate cancer effects. | [in vivo]
UT-34 (20-40 mg/kg; oral administration; daily; for 14 days; NSG mice) at 20 and 40 mg/kg reduces the seminal vesicle weight by 10%-20% and 50%-60 %, respectively[1].
UT-34 inhibits androgen-dependent tissues such as prostate and seminal vesicles in rats, and the growth of Enzalutamide-resistant castration-resistant prostate cancer (CRPC) xenografts. UT-34 also induces tumor regression in intact immunocompromised rats[1]. | Animal Model: | Non obese diabetic/severe combined immunodeficiency Gamma (NSG) mice injected with MR49F cells[1] | | Dosage: | 20 mg/kg or 40 mg/kg | | Administration: | Oral administration; daily; for 14 days | | Result: | Reduced the seminal vesicle weight.
|
| [References]
[1] Ponnusamy S, et al. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6764-6780. DOI:10.1158/1078-0432.CCR-19-1458
[2] Stone L. UT-34: a promising new AR degrader. Nat Rev Urol. 2019 Nov;16(11):640. DOI:10.1038/s41585-019-0248-5 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|